JP2020520368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520368A5 JP2020520368A5 JP2019563558A JP2019563558A JP2020520368A5 JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5 JP 2019563558 A JP2019563558 A JP 2019563558A JP 2019563558 A JP2019563558 A JP 2019563558A JP 2020520368 A5 JP2020520368 A5 JP 2020520368A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- particles
- cancer
- poly
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 28
- 239000002245 particle Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 8
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 238000010255 intramuscular injection Methods 0.000 claims 4
- 239000007927 intramuscular injection Substances 0.000 claims 4
- 230000002601 intratumoral effect Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000008012 organic excipient Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022157413A JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2024131720A JP2024160312A (ja) | 2017-05-17 | 2024-08-08 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171617 | 2017-05-17 | ||
| EP17171617.8 | 2017-05-17 | ||
| EP17382301 | 2017-05-26 | ||
| EP17382301.4 | 2017-05-26 | ||
| EP17200469.9 | 2017-11-07 | ||
| EP17200469 | 2017-11-07 | ||
| PCT/EP2017/079688 WO2018210439A1 (en) | 2017-05-17 | 2017-11-17 | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157413A Division JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020520368A JP2020520368A (ja) | 2020-07-09 |
| JP2020520368A5 true JP2020520368A5 (enExample) | 2021-01-07 |
Family
ID=64273459
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563558A Pending JP2020520368A (ja) | 2017-05-17 | 2017-11-17 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2022157413A Pending JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2024131720A Pending JP2024160312A (ja) | 2017-05-17 | 2024-08-08 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022157413A Pending JP2022188159A (ja) | 2017-05-17 | 2022-09-30 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
| JP2024131720A Pending JP2024160312A (ja) | 2017-05-17 | 2024-08-08 | 二本鎖ポリリボヌクレオチドとポリアルキレンイミンとの複合体を含む粒子を含む新規な医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10849921B2 (enExample) |
| EP (2) | EP3448363B1 (enExample) |
| JP (3) | JP2020520368A (enExample) |
| CN (2) | CN115998757A (enExample) |
| AU (2) | AU2017414660A1 (enExample) |
| CA (1) | CA3063805C (enExample) |
| DK (1) | DK3448363T3 (enExample) |
| ES (1) | ES2924138T3 (enExample) |
| PL (1) | PL3448363T3 (enExample) |
| WO (1) | WO2018210439A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2755418T3 (es) * | 2015-11-17 | 2020-04-22 | Bioncotech Therapeutics S L | Novedosa composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
| ES2924138T3 (es) * | 2017-05-17 | 2022-10-04 | Highlight Therapeutics S L | Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
| WO2020072366A1 (en) * | 2018-10-01 | 2020-04-09 | The Regents Of The University Of California | Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy |
| US20210346420A1 (en) * | 2018-10-10 | 2021-11-11 | The Regents Of The University Of California | Combination immunotherapies |
| US20210396737A1 (en) * | 2018-11-21 | 2021-12-23 | Highlight Therapeutics, S.L. | Nanoplexed poly(i:c) formulations and uses thereof |
| UY39877A (es) * | 2021-07-30 | 2023-02-28 | Esteban Celis | Actividad biológica multidimensional optimizada de poli-iclc con tamaño y formulación de componentes |
| CN114525253B (zh) * | 2022-03-09 | 2024-03-15 | 南开大学 | 一种脂多糖诱导的外泌体及其应用 |
| US20240091348A1 (en) | 2022-09-20 | 2024-03-21 | Highlight Therapeutics, S.L. | Novel compositions based on polyinosinic-polycytidylic acid |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1153931B1 (en) * | 1999-02-15 | 2005-07-20 | Nippon Shinyaku Co., Ltd. | Shortened-chain polynucleotides and process for the preparation thereof |
| US7439349B2 (en) | 2002-07-03 | 2008-10-21 | Andres Salazar | Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof |
| AU2003279509A1 (en) | 2002-11-18 | 2004-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Targeted double stranded rna mediated cell killing |
| US20070166800A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| JP4861036B2 (ja) | 2006-03-31 | 2012-01-25 | リンテック株式会社 | 剥離シートおよびその製造方法 |
| WO2008057696A2 (en) | 2006-10-10 | 2008-05-15 | Juvaris Biotherapeutics, Inc. | Compositions of pattern recognition receptor-ligand: lipid complexes and methods of use thereof |
| KR100958293B1 (ko) | 2008-03-27 | 2010-05-19 | 단국대학교 산학협력단 | 테오필린에 의해 표적 특이적 ｒｎａ 치환 활성이 조절되는알로스테릭 트랜스―스플라이싱 그룹 ｉ 리보자임 |
| WO2009130301A1 (en) * | 2008-04-25 | 2009-10-29 | Institut Gustave Roussy | Improved treatment of cancer using tlr3 agonists in combination with another therapeutic agent |
| DK2379597T3 (en) * | 2008-12-22 | 2016-12-05 | Alexander Levitzki | Double-stranded RNA vector with EGFR as targets for SYSTEMIC CANCER TREATMENT |
| ES2368963B1 (es) | 2009-07-04 | 2012-10-10 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado. |
| CN102988303A (zh) | 2011-09-15 | 2013-03-27 | 天津泽世德生物医药有限公司 | 一种多聚肌苷酸多聚胞苷酸冻干粉针的制备方法 |
| US20140234373A1 (en) | 2011-09-16 | 2014-08-21 | Georfia Regents University | Methods of Promoting Immune Tolerance |
| US9226936B2 (en) | 2011-10-28 | 2016-01-05 | The Wistar of Anatomy and Biology | Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells |
| EP2790674B1 (en) | 2011-12-15 | 2017-11-01 | BioNTech AG | Particles comprising single stranded rna and double stranded rna for immunomodulation |
| US9682096B2 (en) | 2012-05-02 | 2017-06-20 | Janssen R & D Ireland | Polyinosinic-polycytidylic acid (poly (I:C)) formulations for the treatment of upper respiratory tract infections |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| WO2014165296A1 (en) | 2013-03-12 | 2014-10-09 | Multicell Immunotherapeutics, Inc. | Methods and formulations to achieve tumor targeted double stranded rna mediated cell death |
| WO2015067632A1 (en) | 2013-11-06 | 2015-05-14 | Janssen Sciences Ireland Uc | Polylnosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| CN103599071B (zh) | 2013-11-08 | 2016-01-27 | 杭州美亚药业股份有限公司 | 一种双链聚肌胞干粉的制备方法 |
| RU2771104C2 (ru) | 2014-05-14 | 2022-04-26 | Таргиммьюн Терапьютикс Аг | Улучшенные полиэтилениминовые полиэтиленгликолевые векторы |
| WO2016165825A1 (en) | 2015-04-13 | 2016-10-20 | Curevac Ag | Method for producing rna compositions |
| SG11201708760PA (en) * | 2015-05-05 | 2017-11-29 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Nucleic acid-cationic polymer compositions and methods of making and using the same |
| ES2755418T3 (es) * | 2015-11-17 | 2020-04-22 | Bioncotech Therapeutics S L | Novedosa composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
| CN109715205A (zh) | 2016-08-19 | 2019-05-03 | 库瑞瓦格股份公司 | 用于癌症治疗的rna |
| ES2924138T3 (es) * | 2017-05-17 | 2022-10-04 | Highlight Therapeutics S L | Nueva composición farmacéutica que comprende partículas que comprenden un complejo de un polirribonucleótido de doble cadena y una polialquilenimina |
-
2017
- 2017-11-17 ES ES17804148T patent/ES2924138T3/es active Active
- 2017-11-17 DK DK17804148.9T patent/DK3448363T3/da active
- 2017-11-17 AU AU2017414660A patent/AU2017414660A1/en not_active Abandoned
- 2017-11-17 JP JP2019563558A patent/JP2020520368A/ja active Pending
- 2017-11-17 US US16/614,439 patent/US10849921B2/en active Active
- 2017-11-17 EP EP17804148.9A patent/EP3448363B1/en active Active
- 2017-11-17 PL PL17804148.9T patent/PL3448363T3/pl unknown
- 2017-11-17 WO PCT/EP2017/079688 patent/WO2018210439A1/en not_active Ceased
- 2017-11-17 CN CN202310100333.0A patent/CN115998757A/zh active Pending
- 2017-11-17 EP EP22172379.4A patent/EP4122449A1/en active Pending
- 2017-11-17 CA CA3063805A patent/CA3063805C/en active Active
- 2017-11-17 CN CN201780092798.9A patent/CN110831581A/zh active Pending
-
2019
- 2019-12-23 US US16/724,519 patent/US10869881B2/en active Active
-
2020
- 2020-10-30 US US17/084,995 patent/US11883424B2/en active Active
- 2020-11-11 US US17/095,059 patent/US11896606B2/en active Active
-
2022
- 2022-09-30 JP JP2022157413A patent/JP2022188159A/ja active Pending
- 2022-11-16 US US17/988,625 patent/US12383575B2/en active Active
-
2024
- 2024-07-10 AU AU2024204758A patent/AU2024204758A1/en active Pending
- 2024-08-08 JP JP2024131720A patent/JP2024160312A/ja active Pending
-
2025
- 2025-07-07 US US19/261,229 patent/US20250332191A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020520368A5 (enExample) | ||
| Wehbe et al. | Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration | |
| Han et al. | Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer | |
| Gao et al. | Encapsulation of platinum prodrugs into PC7A polymeric nanoparticles combined with immune checkpoint inhibitors for therapeutically enhanced multimodal chemotherapy and immunotherapy by activation of the STING pathway | |
| Norouzi et al. | Injectable hydrogel-based drug delivery systems for local cancer therapy | |
| Guorgui et al. | Curcumin formulated in solid lipid nanoparticles has enhanced efficacy in Hodgkin's lymphoma in mice | |
| Talelli et al. | Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy | |
| Shang et al. | Enhancing cancer chemo-immunotherapy by biomimetic nanogel with tumor targeting capacity and rapid drug-releasing in tumor microenvironment | |
| Barzegar Behrooz et al. | Smart bomb AS 1411 aptamer‐functionalized/PAMAM dendrimer nanocarriers for targeted drug delivery in the treatment of gastric cancer | |
| Zhou et al. | Nanoparticle‐mediated STING agonist delivery for enhanced cancer immunotherapy | |
| Zhang et al. | Metal coordination‐driven assembly of stimulator of interferon genes‐activating nanoparticles for tumor chemo‐immunotherapy | |
| Yu et al. | Synergy of immunostimulatory genetherapy with immune checkpoint blockade motivates immune response to eliminate cancer | |
| Stigliano et al. | Radiolabeled polymeric nanoconstructs loaded with docetaxel and curcumin for cancer combinatorial therapy and nuclear imaging | |
| Paolino et al. | Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer | |
| US10632081B2 (en) | Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis | |
| Wang et al. | Folate-mediated targeted PLK1 inhibition therapy for ovarian cancer: a comparative study of molecular inhibitors and siRNA therapeutics | |
| Li et al. | EGF‐functionalized lipid–polymer hybrid nanoparticles of 5‐fluorouracil and sulforaphane with enhanced bioavailability and anticancer activity against colon carcinoma | |
| Mollica et al. | Delivery methods of camptothecin and its hydrosoluble analogue irinotecan for treatment of colorectal cancer | |
| Yan et al. | Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy | |
| Li et al. | Co-delivery of Interleukin-12 and doxorubicin loaded Nano-delivery system for enhanced immunotherapy with polarization toward M1-type Macrophages | |
| Kazemi et al. | PNA-ATP aptamer-capped doxorubicin-loaded silica nanoparticles for targeted cancer therapy | |
| CN101869712A (zh) | 使用包囊抗肿瘤药物的聚合胶束用于治疗肿瘤的药物组合物 | |
| Jiang et al. | Nanoscale coordination polymer synergizes photodynamic therapy and toll-like receptor activation for enhanced antigen presentation and antitumor immunity | |
| Fu et al. | Peptide modified albumin–paclitaxel nanoparticles for improving chemotherapy and preventing metastasis | |
| Zhu et al. | Tumor immune microenvironment-modulated nanostrategy for the treatment of lung cancer metastasis |